A phase 3 study of SCY-078 in patients with acute Vulvovaginal Candidiasis

Trial Profile

A phase 3 study of SCY-078 in patients with acute Vulvovaginal Candidiasis

Planning
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs SCY 078 (Primary)
  • Indications Vulvovaginal candidiasis
  • Focus Registrational; Therapeutic Use
  • Sponsors SCYNEXIS
  • Most Recent Events

    • 19 Mar 2018 New trial record
    • 13 Mar 2018 According to a SCYNEXIS media release, the company anticipates initiating this Phase 3 study in the fourth quarter of 2018, with the objective of filing the New Drug Application (NDA) for acute VVC in 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top